24 Oct 2018 I The release and presentation materials are now available.
|10/30/2018||Composition of the Nomination Committee of Orion Corporation|
|10/24/2018||Orion Group Interim Report January-September 2018|
|10/24/2018||Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met|
|9/19/2018||Changes in responsibility areas of the Orion Group Executive Management Board|
|11/1/2018||Orion Research Foundation grants million euros for research in 2019|
|10/24/2018||Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland|
|10/10/2018||Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018|
|9/17/2018||Creation of novel medicines and better patient care for the future in an ecosystem|
The Closing of the transaction took place on 30 April 2018.
Orion's key research projects include three ongoing Phase III trials, among others.
The 2018 Annual General Meeting of Orion was held on Tuesday, 20 March 2018 in Helsinki.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
The latest Corporate Governance Statement of Orion Corporation is available at the archive of Corporate Governance Statements.